These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.

This document has been updated:  Version 18 August 2022.

For translations of this document in other languages, click here.

Related documents:

Archived versions:

  • Position paper
  • Pfizer-BioNTech vaccine
  • COVID-19